Provided by Tiger Fintech (Singapore) Pte. Ltd.

TransCode Therapeutics Inc.

0.3621
-0.0604-14.30%
Post-market: 0.36990.0078+2.15%19:59 EDT
Volume:2.25M
Turnover:846.07K
Market Cap:8.45M
PE:-0.01
High:0.4100
Open:0.4090
Low:0.3521
Close:0.4225
Loading ...

TransCode Therapeutics Announces Reverse Stock Split

TIPRANKS
·
Yesterday

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

PR Newswire
·
Yesterday

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday

Benzinga
·
05 May

BRIEF-Transcode Therapeutics Announces 1-For-28 Reverse Stock Split

Reuters
·
03 May

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split

MT Newswires Live
·
03 May

Transcode Therapeutics announces 1-for-28 reverse stock split

TIPRANKS
·
03 May

TransCode Therapeutics Approves 1-for-28 Reverse Stock Split to Meet Nasdaq Requirements

Reuters
·
03 May

Transcode Therapeutics Inc - Approves 1-for-28 Reverse Stock Split

THOMSON REUTERS
·
03 May

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TIPRANKS
·
02 May

Transcode Therapeutics Inc - Two Patients Maintain Stable Disease for Seven Months

THOMSON REUTERS
·
01 May

Transcode Therapeutics Reports Further Progress on Phase 1a Clinical Trial With No Dose Limiting Toxicities Reported in Patients With Metastatic Cancer

THOMSON REUTERS
·
01 May

Transcode Therapeutics Inc - Ttx-Mc138 Well Tolerated at Highest Dose

THOMSON REUTERS
·
01 May

Transcode Therapeutics Inc - Pd Analysis Shows Mir-10B Target Engagement Post-Dosing

THOMSON REUTERS
·
01 May

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

PR Newswire
·
01 May

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

Benzinga
·
01 May

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

PR Newswire
·
22 Apr

Transcode Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
16 Apr

TransCode Therapeutics Delays Annual Report Filing

TIPRANKS
·
01 Apr

TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial

MT Newswires Live
·
28 Mar

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

PR Newswire
·
28 Mar